Direct Biologics Announces FDA Authorization to Expand Ongoing Phase 3 Clinical Study of ExoFlo™ to All-Cause Moderate-to-Severe ARDS

Direct Biologics, LLC announced that the FDA has authorized the expansion of its pivotal Phase 3 EXTINGUISH ARDS trial to evaluate the safety and efficacy of ExoFlo™ in the treatment of moderate-to-severe acute respiratory distress syndrome (ARDS) from any underlying etiology.